Vericel Corp. (VCEL) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Harmony Biosciences Holdings, Inc.

Vericel Corp.

Madrigal Pharmaceuticals, Inc.

Cytokinetics, Inc.

PTC Therapeutics, Inc.

Xenon Pharmaceuticals, Inc.

Ultragenyx Pharmaceutical, Inc.

Amphastar Pharmaceuticals, Inc.

Akero Therapeutics, Inc.

Biohaven Ltd.

Neumora Therapeutics, Inc.

Why is Vericel Corp. ?

Poor Management Efficiency with a low ROE of 0.85%

The company has been able to generate a Return on Equity (avg) of 0.85% signifying low profitability per unit of shareholders funds

Poor long term growth as Operating profit has grown by an annual rate 25.01% of over the last 5 years

The company declared negative results in Mar'25 after very positive results in Dec'24

NET PROFIT(HY) At USD -11.8 MM has Grown at -38.1%
DEBT-EQUITY RATIO (HY) Highest at -5 %

With ROE of 1.01%, it has a attractive valuation with a 7.38 Price to Book Value

Over the past year, while the stock has generated a return of -27.43%, its profits have risen by 253% ; the PEG ratio of the company is 1.4

High Institutional Holdings at 100%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.

Underperformed the market in the last 1 year

Even though the market (S&P 500) has generated returns of 12.33% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -27.43% returns

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Vericel Corp. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Vericel Corp. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Vericel Corp.

-36.83%

-0.05

48.87%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

16.40%

EBIT Growth (5y)

25.01%

EBIT to Interest (avg)

-6.44

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.37

Sales to Capital Employed (avg)

0.84

Tax Ratio

4.73%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

1.36%

ROE (avg)

0.85%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

732

Industry P/E

Price to Book Value

7.38

EV to EBIT

-737.63

EV to EBITDA

517.61

EV to Capital Employed

11.04

EV to Sales

8.69

PEG Ratio

1.35

Dividend Yield

ROCE (Latest)

-1.50%

ROE (Latest)

1.01%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

Mildly Bearish

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

9What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD 47.23 MM

RAW MATERIAL COST(Y)

Fallen by -6.15% (YoY

PRE-TAX PROFIT(Q)

At USD -0.55 MM has Grown at 88.19%

NET PROFIT(Q)

At USD -0.55 MM has Grown at 88.19%

-5What is not working for the Company

NET PROFIT(HY)

At USD -11.8 MM has Grown at -38.1%

DEBT-EQUITY RATIO (HY)

Highest at -5 %

Here's what is working for Vericel Corp.

Operating Cash Flow

Highest at USD 47.23 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Pre-Tax Profit

At USD -0.55 MM has Grown at 88.19%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit

At USD -0.55 MM has Grown at 88.19%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

Raw Material Cost

Fallen by -6.15% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation

Highest at USD 2.83 MM

in the last five periods

MOJO Watch

The expenditure on assets done by the company may have gone into operation

Depreciation (USD MM)

Here's what is not working for Vericel Corp.

Debt-Equity Ratio

Highest at -5 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio